Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12476441 | 0.86 | HDAC8 (0.36) | HDAC8HDAC6F10PLK1F2 | |
| SCHEMBL9893361 | 0.85 | LOXL2 (0.42) | SLC7A5KMT2ATSHRSMN1; SMN2KDM4E | |
| SCHEMBL13571463 | 0.85 | RXRA (0.40) | F2KMT2AMRGPRX4HPGDSMN1; SMN2 | |
| SCHEMBL6607443 | 0.84 | PLAU (0.49) | F10PLK1PLAUHPGDTSHR | |
| SCHEMBL4429925 | 0.84 | HSD17B10 (0.41) | L3MBTL1MEN1KMT2AMRGPRX4LOX | |
| SCHEMBL15192320 | 0.82 | ATM (0.46) | L3MBTL1HPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1366312 | 0.81 | ALDH1A1 (0.44) | MEN1KMT2AMRGPRX4ALDH1A1 | |
| SCHEMBL6610483 | 0.80 | HPGD (0.41) | HDAC8HDAC6PLK1HPGDTSHR | |
| SCHEMBL2208561 | 0.79 | FYN (0.47) | L3MBTL1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL9893898 | 0.79 | CYP4F2 (0.44) | F10KMT2AHPGDTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273260-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2672820-B1 | MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF | UNIV WASHINGTON (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170247401-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | WASHINGTON UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-9567362-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150197538-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-07-16 | — | — | US | disclosed |
| US-8937167-B2 | Compounds and methods for treating bacterial infections | WASHINGTON UNIVERSITY (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2672820-A1 | MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF | The Washington University (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | THE WASHINGTON UNIVERSITY (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012109263-A1 | MANNOSIDE COMPOUNDS AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273260-B2 | Compounds and methods for treating bacterial infections | MMP8, ELANE, GUSB | HDAC8 1770/4885HDAC6 125/4885SLC7A5 2930/4885 |
| US-20120309701-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | HDAC8 1770/4885HDAC6 125/4885SLC7A5 2930/4885 |
| US-20170247401-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | HDAC8 1770/4885HDAC6 125/4885SLC7A5 2930/4885 |
| US-20150197538-A1 | COMPOUNDS AND METHODS FOR TREATING BACTERIAL INFECTIONS | MMP8, ELANE, GUSB | HDAC8 1770/4885HDAC6 125/4885SLC7A5 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.